KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has been selected for presentations at
Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for
Radnor, PA, USA – January 2, 2023 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company developing
Radnor, PA, USA – November 10, 2022 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company developing
FDA supports the initiation of Aclipse Therapeutics’ Phase 2 development of M107for Idiopathic Gastropareses Radnor, PA, USA – July 18, 2022 – Aclipse Therapeutics and
Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has received a therapeutic
CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He
Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis Radnor, PA — January 26, 2021 – Aclipse
Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in
Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary